Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Smacked By Treasury Anti-Inversion Actions

This article was originally published in Scrip

Executive Summary

Allergan PLC investors panicked on April 4, driving shares of the firm down 22% in after-hours trading, over concerns new anti-inversion actions unleashed by the US Treasury Department would get in the way of the company's plans to merge under a $160bn deal with Pfizer Inc., whose own stock actually gained about 3%.

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC064897

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel